|Bid||8.90 x 2200|
|Ask||9.07 x 800|
|Day's Range||8.79 - 9.48|
|52 Week Range||6.66 - 16.37|
|Beta (5Y Monthly)||1.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 13, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.40|
Biogen (NASDAQ: BIIB) stock rocketed to a six-year high earlier this week on news that its therapy, aducanumab, was the first Alzheimer's drug approved in nearly 20 years by the U.S. Food and Drug Administration (FDA). This is a huge deal, not only for Alzheimer's patients, but for Biogen and its shareholders. There are two other biotech stocks, however, whose recent breakthroughs could drive the profits for years to come, and they are still priced modestly -- for now.
Alpine Immune Sciences set to join Russell 3000® Index
Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shareholders will have a reason to smile today, with the analysts making...